Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin

Bone Marrow Transplantation

Volumn 26, Issue 2, 2000, Pages 119-125

  Bornhauser M ^a   Thiede, C ^a   Schuler, U ^a   Platzbecker, U ^a   Freiberg Richter, J ^a   Helwig, A ^a   Plettig, R ^a   Rollig C ^a   Naumann, R ^a   Kroschinsky, F ^a   Neubauer, A ^a   Ehninger, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antithymocyte globulin; Dose reduced conditioning; Transplant related mortality

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BUSULFAN; CIPROFLOXACIN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALLOTRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; INFECTION COMPLICATION; LEUKEMIA; LYMPHOMA; MALE; NEUROTOXICITY; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SIBLING; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 18544394289     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702500     Document Type: Article

References (26)

1. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
2. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
3. Colson YL, Wren SM, Schuchert MJ et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995; 155: 4179-4188.
4. Kimikawa M, Sachs DH, Colvin RB et al. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709-715.
5. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
6. Khouri I, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
7. McSweeney PA, Wagner JL, Maloney DG et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood 1998; 92 (Suppl. 1): 519 (Abstr. 2133).
8. Ottinger HD, Albert E, Arnold R et al. German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells. Bone Marrow Transplant 1997; 20: 101-105.
9. Ehninger G, Schuler U, Renner U et al. Use of a water-soluble busulfan formulation - pharmacokinetic studies in a canine model. Blood 1995; 85: 3247-3249.
10. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
11. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
12. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
13. Thiede C, Florek M, Bornhäuser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-462.
15. deMagalhaes SM, Bloom EJ, Donnenberg A et al. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 329-333.
16. Miralbell R, Bieri S, Mermillod B et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 1996; 14: 579-585.
17. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
18. Colson YL, Li H, Boggs SS et al. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820-2829.
19. Bunn D, Lea CK, Bevan DJ et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996; 45: 29-32.
20. Gyger M, Baron C, Forest L et al. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs-host disease. Exp Hematol 1998; 26: 426-434.
21. Thiede C, Brendel C, Mohr B et al. Comparative analysis of chimerism in the early post-transplantation period in cellular subsets of patients undergoing myeloablative and nonmyeloablative allogeneic blood stem cell transplantation. Blood 1998; 92 (Suppl. 1): 132 (abstr. 533).
22. Stewart FM, Zhong S, Wuu J et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 1998; 91: 3681-3687.
23. Dearden C, Foukaneli T, Lee P et al. The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anaemia. Br J Haematol 1998; 103: 846-848.
24. Bacigalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
25. Krogsgaard K, Boesgaard S, Aldershvile J et al. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. Scand J Infect Dis 1994; 26: 239-247.
26. Childs RW, Clave E, Tisdale J et al. Sucessful treatment of metastatic renal cell carcinoma with nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2049.